The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Pfizer
Dmitry Nosov
No relevant relationships to disclose
Piotr Tomczak
No relevant relationships to disclose
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer